| Literature DB >> 35505434 |
Yilong Guo1,2, Zhensu Shi2, Yue Shu3,4, Dexing Zhou5, Yin Zheng6, Caichan Xie2, Jiao Yi2, Zelun Chen2.
Abstract
BACKGROUND: A patent foramen ovale (PFO) is a risk factor for cryptogenic stroke (CS), and interventional therapy for PFO can reduce the recurrence rate of CS. However, interventional therapies are primarily guided by X-ray imaging, and data on regular post-surgical follow-up with the transthoracic ultrasound foaming test (UFT) are rare. Thus, this study aimed to assess the short-term (12 months) results of PFO occlusion guided by transoesophageal echocardiography (TEE) and the results of regular UFTs.Entities:
Keywords: Cryptogenic stroke; Interventional therapy; Patent foramen ovale; Transoesophageal echocardiography; Ultrasound foaming test
Mesh:
Year: 2022 PMID: 35505434 PMCID: PMC9066844 DOI: 10.1186/s13019-022-01845-3
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.522
Clinical characteristics of the study population
| Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | ||
|---|---|---|---|---|
| Female sex | 14 (66.67%) | 11 (50.00%) | 12 (37.50%) | 0.119 |
| Age (mean ± SD, years) | 45.05 ± 8.992 | 45.09 ± 9.314 | 41.25 ± 10.352 | 0.247 |
| Weight (mean ± SD, kg) | 60.92 ± 7.855 | 59.59 ± 11.548 | 56.72 ± 8.938 | 0.263 |
| Height (mean ± SD, cm) | 163.05 ± 7.965 | 160.68 ± 7.656 | 160.06 ± 5.224 | 0.287 |
| Diabetes | 2 (9.52%) | 4 (18.18%) | 1 (3.13%) | 0.178 |
| Hypertension | 7 (33.33%) | 8 (36.36%) | 7 (21.88%) | 0.467 |
| Hyperlipidaemia | 1 (4.76%) | 4 (18.18%) | 1 (3.13%) | 0.112 |
| Heart function (NYHA) | 0.462 | |||
| I | 8 | 4 | 7 | |
| II | 10 | 14 | 21 | |
| III | 3 | 4 | 4 | |
| Recurrence stroke before surgery | 3 | 3 | 4 | 0.982 |
| Stroke sequelae before surgery | 1 | 1 | 3 | 0.719 |
SD standard deviation, NYHA New York Heart Association
Echocardiographic characteristics of the study population
| Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | ||
|---|---|---|---|---|
| RV (mm) | 23.24 ± 2.879 | 22.05 ± 4.326 | 21.47 ± 4.333 | 0.290 |
| LA (mm) | 31.48 ± 5.437 | 29.45 ± 3.776 | 28.69 ± 5.515 | 0.147 |
| PA (mm) | 21.29 ± 3.036 | 20.32 ± 2.255 | 20.47 ± 3.233 | 0.500 |
| LVEDD (mm) | 43.81 ± 2.839 | 42.82 ± 3.187 | 42.72 ± 2.667 | 0.367 |
| LVEF (%) | 63.00 ± 6.116 | 65.50 ± 2.596 | 64.98 ± 5.097 | 0.205 |
| PSP (mmHg) | 22.62 ± 4.031 | 23.09 ± 3.531 | 24.44 ± 2.590 | 0.121 |
| PVR (dyn s cm−5) | 150.10 ± 26.474 | 164.55 ± 20.871 | 158.47 ± 24.397 | 0.149 |
RV right ventricular, LA left atrial, PA main pulmonary artery, LVEDD left ventricular end-diastolic diameter, LVEF, left ventricular ejection fraction, PSP pulmonary systolic pressure, PVR pulmonary vascular resistance
Perioperative data of the study population
| Group A (n = 21) | Group (n = 22) | Group C (n = 32) | ||
|---|---|---|---|---|
| Time (min) | 44.71 ± 25.714 | 35.64 ± 20.984 | 38.50 ± 25.821 | 0.464 |
| Length of PFO (mm) | 9.03 ± 4.616a | 10.55 ± 3.546b | 14.021 ± 3.047a,b | < 0.001 |
| Occluder (mm) | 19.67 ± 3.055a | 19.91 ± 3.191b | 23.25 ± 3.800a,b | < 0.001 |
| Oesophageal bleeding | 2 | 3 | 3 | 0.866 |
| Length of stay (days) | 12.24 ± 6.480 | 13.50 ± 8.478 | 13.00 ± 8.658 | 0.875 |
Statistical comparisons: comparison between groups, ap < 0.01; bp < 0.05
PFO patent foramen ovale
Fig. 1Transthoracic echocardiography shows blood flow after PFO occlusion. No residual shunt is noted between the LA and RA. LV left ventricular, LA left atrial, RV right ventricular, RA right atrial, PFO patent foramen ovale
Fig. 2Negative transthoracic UFT result after PFO occlusion. There is no microbubble in the LA. LV left ventricular, RA right atrial, LA left atrial, PFO patent foramen ovale, UFT ultrasound foaming test
Fig. 3Positive transthoracic UFT result after PFO occlusion. There are more than 25 microbubbles in the LA and LV. LV left ventricular, RA right atrial, LA left atrial, PFO patent foramen ovale, UFT ultrasound foaming test
Positive results of UFT during follow-up
| Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | |
|---|---|---|---|
| Three months | 17 (80.95%) | 21 (95.45%) | 32 (100%) |
| Six months | 8 (38.10%) | 13 (59.09%) | 31 (96.88%) |
| Nine months | 2 (9.52%) | 7 (31.82%) | 23 (71.88%) |
| Twelve months | 0 (0) | 3 (13.64%) | 16 (50.00%) |
UFT ultrasound foaming test
Fig. 4Life-table analysis: the cumulative positive UFT rate for all patients. UFT ultrasound foaming test
Fig. 5Cox regression analysis: the cumulative positive UFT rate for different groups. UFT ultrasound foaming test